Immunotherapy pioneer Carl June, MD, was named member of the 2017 class of fellows of the American Association for Cancer Research (AACR) Academy in April 2017, in recognition for his pivotal role in designing chimeric antigen receptor T cell immunotherapy (CAR-T) for the treatment of relapsed/refractory chronic lymphocytic leukemia.
Dr. June is director of the Center for Cellular Immunology in the Abramson Cancer Center and director of the Parker Institute for Cancer Immunotherapy at University of Pennsylvania School of Medicine.
When asked by OBR what this award means to him, Dr. June replied: “The AACR fellowship was a very special award for several reasons. First, the previous inductees are in many cases my most revered colleagues and mentors, who are literally the ‘Who’s who’ of cancer research. Secondly, the induction ceremony led by AACR leadership was very special.”
Dr. June began his research on genetically modified T cells in the 1990s when he was studying HIV/AIDS. This work led to his studying this technology in leukemia and the first clinical trials in leukemia patients in 2010. At that time, only three cancer centers had open CAR-T trials; now more than 110 CAR-T trials are open in the U.S. and other countries.
CAR-T cell therapy is still a work in progress. Although this therapy has achieved dramatic results in some patients with no other treatment options, it can also unleash the immune system to go awry, so much attention has focused on optimizing outcomes while taming unwanted immune responses.
The first pediatric patient to receive CAR-T therapy was Emily Whitehead, a 7-year-old child with intractable, seemingly fatal acute lymphoblastic leukemia. Her miraculous recovery made front-page headlines and she is alive and in remission at age 10.
Since then, scores of other patients with leukemias and other hematologic cancers have received CAR-T, with excellent and unprecedented remissions in many patients. The therapy is furthest along in development for the treatment of acute lymphocytic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma, and approval by the FDA is expected sometime in 2017.
CAR-T is also investigational in multiple myeloma and acute myeloid leukemia and in some sold tumors.
Dr. June continues his research on CAR-T and how best to exploit this novel approach. “The fundamental goal of CAR-T research is to contribute to the ultimate solution for cancer: curing and preventing,” he told OBR.
By John McCleery
You must be logged in to post a comment